Emergent BioSolutions Closes On Its Acquisition Of Healthcare Protective Products Division From Bracco Diagnostics Inc.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has closed on its acquisition of Bracco Diagnostics Inc.’s Healthcare Protective Products Division. This acquisition, which includes the RSDL ® (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent’s biodefense franchise into the chemical countermeasure market.

“As a result of this transaction closing, Emergent is focused on the uninterrupted supply of RSDL product to customers and on the seamless integration of the new Healthcare Protective Products Group (HPPG) into our biodefense division,” said Adam Havey, EVP and president of Emergent’s biodefense division. “This news, which comes on the heels of other positive developments in our biodefense division, including receiving BioThrax ® (Anthrax Vaccine Adsorbed) market authorization in Germany as well as reporting positive data from our pivotal study supporting licensure of a post-exposure prophylaxis indication for BioThrax, reinforces Emergent’s leadership position in the biodefense arena.”

The Canadian Department of National Defence and the U.S. Department of the Army have both played a central role in the development and licensing of RSDL, which is also cleared for sale by Health Canada, the U.K. Medicines and Healthcare Products Regulatory Agency, and Australia’s Therapeutics Goods Administration.

The closing on this acquisition contemplates that certain additional assets will be transferred to the company by year end. The company will discuss the impact of this acquisition to Emergent’s anticipated revenue and net income for full year 2013 during the company’s 2Q 2013 financial results call scheduled for August 5, 2013.

About Emergent BioSolutions

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the potential opportunities and financial impact of the transaction, and our financial guidance, and any other statements containing the words “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates” and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to successfully integrate the business and realize the benefits of the transaction; appropriations for BioThrax ® procurement; our ability to obtain new BioThrax sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax; availability of funding for our U.S. government grants and contracts; our ability to identify and acquire or in-license products or late-stage product candidates that satisfy our selection criteria; whether anticipated synergies and benefits from an acquisition or in-license are realized within expected time periods or at all; our ability to enter into selective collaboration arrangements; our ability to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Copyright Business Wire 2010